AgomAb Therapeutics NV ADR(AGMB)
$5.97-0.39 (-6.13%)
AGMB
AgomAb Therapeutics NV ADR financials statements
$5.97
At close:-0.39 (-6.13%)
AgomAb Therapeutics NV ADR (AGMB) Ratios
42 Followers
AgomAb Therapeutics NV ADR Ratios
AGMB's free cash flow for Q4 2025 was €-13.18M. For the 2025 fiscal year, AGMB's free cash flow was decreased by €-4.00K and operating cash flow was €-13.17M. See a summary of the company’s cash flow.
| Ratios | Mar 26 |
|---|---|
| Liquidity Ratios | |
| Current Ratio | 6.52 |
| Quick Ratio | 6.52 |
| Cash Ratio | 4.65 |
| Solvency Ratio | -2.73 |
| Operating Cash Flow Ratio | -2.78 |
| Short-Term Operating Cash Flow Coverage | 0.00 |
| Net Current Asset Value | € 98.43M |
| Leverage Ratios | |
| Debt-to-Assets Ratio | 0.01 |
| Debt-to-Equity Ratio | 0.01 |
| Debt-to-Capital Ratio | 0.01 |
| Long-Term Debt-to-Capital Ratio | 0.00 |
| Financial Leverage Ratio | 1.17 |
| Debt Service Coverage Ratio | -1037.80 |
| Interest Coverage Ratio | -987.92 |
| Debt to Market Cap | 0.00 |
| Interest Debt Per Share | 0.03 |
| Net Debt to EBITDA | 1.37 |
| Profitability Margins | |
| Gross Profit Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Profit Margin | 0.00% |
| Pretax Profit Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Continuous Operations Profit Margin | 0.00% |
| Net Income Per EBT | 100.00% |
| EBT Per EBIT | 105.52% |
| Return on Assets (ROA) | -40.69% |
| Return on Equity (ROE) | -47.78% |
| Return on Capital Employed (ROCE) | -43.87% |
| Return on Invested Capital (ROIC) | -43.79% |
| Return on Tangible Assets | -52.13% |
| Earnings Yield | -10.29% |
| Efficiency Ratios | |
| Receivables Turnover | 0.00 |
| Payables Turnover | 0.00 |
| Inventory Turnover | 0.00 |
| Fixed Asset Turnover | 0.00 |
| Asset Turnover | 0.00 |
| Working Capital Turnover Ratio | 0.00 |
| Cash Conversion Cycle | 0.00 |
| Days of Sales Outstanding | 0.00 |
| Days of Inventory Outstanding | 0.00 |
| Days of Payables Outstanding | 0.00 |
| Operating Cycle | 0.00 |
| Cash Flow Ratios | |
| Operating Cash Flow Per Share | -1.06 |
| Free Cash Flow Per Share | -1.06 |
| Dividend Paid and CapEx Coverage Ratio | -12935.25 |
| Capital Expenditure Coverage Ratio | -12935.25 |
| Operating Cash Flow Coverage Ratio | -41.26 |
| Operating Cash Flow to Sales Ratio | 0.00 |
| Free Cash Flow Yield | -8.52% |
| Valuation Ratios | |
| Price-to-Earnings (P/E) Ratio | -9.74 |
| Price-to-Sales (P/S) Ratio | 0.00 |
| Price-to-Book (P/B) Ratio | 4.64 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -11.74 |
| Price-to-Operating Cash Flow Ratio | -11.74 |
| Price-to-Earnings Growth (PEG) Ratio | -6.14 |
| Enterprise Value Multiple | -8.39 |
| Enterprise Value | 522.52M |
| EV to EBITDA | -8.39 |
| EV to Sales | 0.00 |
| EV to Free Cash Flow | -10.10 |
| EV to Operating Cash Flow | -10.10 |
| Tangible Book Value Per Share | 1.99 |
| Shareholders’ Equity Per Share | 2.69 |
| Tax and Other Ratios | |
| Effective Tax Rate | 0.00 |
| Revenue Per Share | 0.00 |
| Net Income Per Share | -1.28 |
| Tax Burden | 1.00 |
| Interest Burden | 1.00 |
| Research & Development to Revenue | 0.00 |
| SG&A to Revenue | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 |
| Income Quality | 0.83 |
Currency in EUR

